Immutep Ltd

Research Immutep Ltd (IMMP) on Bullrun: market cap USD 59.33M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerIMMP
• ExchangeNASDAQ
• CountryAustralia
• SectorHealthcare
• IndustryBiotechnology
• CurrencyUSD
• Market capUSD 59.33M
• Financial periodQ1 2026
• Free cash flowUSD 13.51M

Valuation Snapshot

latest market cap is USD 59.33M.

About Immutep Ltd

Immutep Limited, a biotechnology company, engages in developing novel Lymphocyte Activation Gene-3 related immunotherapies for cancer and autoimmune diseases in Australia. Its lead product candidate is the eftilagimod alfa (efti or IMP321), a soluble LAG-3lg fusion based on LAG-3 immune control mechanism for the treatment of different types of cancers. The company's product pipeline also includes TACTI-004, which is in phase III clinical trial for the treatment of first line non-small cell lung cancer (1L NSCLC);

Frequently asked questions

What is Immutep Ltd's market cap?

Immutep Ltd's market capitalization is USD 59.33M.

What does Immutep Ltd do?

Immutep Limited, a biotechnology company, engages in developing novel Lymphocyte Activation Gene-3 related immunotherapies for cancer and autoimmune diseases in Australia.